- Research article
- Open Access
- Open Peer Review
Establishment and characterization of pleomorphic adenoma cell systems: an in-vitro demonstration of carcinomas arising secondarily from adenomas in the salivary gland
© Maruyama et al; licensee BioMed Central Ltd. 2009
- Received: 14 October 2008
- Accepted: 21 July 2009
- Published: 21 July 2009
Among the salivary gland carcinomas, carcinoma in pleomorphic adenoma has been regarded as a representative carcinoma type which arises secondarily in the background of a pre-existent benign pleomorphic adenoma. It is still poorly understood how and which benign pleomorphic adenoma cells transform into its malignant form, carcinoma ex pleomorphic adenoma.
We have established five cell systems from a benign pleomorphic adenoma of the parotid gland of a 61-year-old woman. They were characterized by immunofluorescence, classical cytogenetics, p53 gene mutational analysis, fluorescence in-situ hybridization, and histopathological and immunohistochemical examinations of their xenografts, to demonstrate their potency of secondary transformation.
We established and characterized five cell systems (designated as SM-AP1 to SM-AP5) from a benign pleomorphic adenoma of the parotid gland. SM-AP1 to SM-AP3 showed polygonal cell shapes while SM-AP4 and SM-AP5 were spindle-shaped. SM-AP1-3 cells were immunopositive for keratin only, indicating their duct-epithelial or squamous cell differentiation, while SM-AP4/5 cells were positive for both keratin and S-100 protein, indicating their myoepithelial cell differentiation. Chromosome analyses showed numeral abnormalities such as 5n ploidies and various kinds of structural abnormalities, such as deletions, translocations, derivatives and isodicentric chromosomes. Among them, der(9)t(9;13)(p13.3;q12.3) was shared by all five of the cell systems. In addition, they all had a common deletion of the last base G of codon 249 (AGG to AG_) of the p53 gene, which resulted in generation of its nonsense gene product. Transplanted cells in nude mice formed subcutaneous tumors, which had histological features of squamous cell carcinoma with apparent keratinizing tendencies. In addition, they had ductal arrangements or plasmacytoid appearances of tumor cells and myxoid or hyaline stromata, indicating some characteristics of pleomorphic adenoma.
This study demonstrates in vitro that certain cell types from pleomorphic adenoma are able to clone and survive over a long term and develop subcutaneous tumors in nude mice. The histological features of squamous cell carcinoma from the transplanted cell systems in nude mice might suggest a secondary onset of malignancy from a pre-existing benign adenoma.
- Bacterial Artificial Chromosome
- Bacterial Artificial Chromosome Clone
- Pleomorphic Adenoma
- Oral Squamous Cell Carcinoma
- Salivary Gland Carcinoma
Among the salivary gland carcinomas, carcinoma ex pleomorphic adenoma has been regarded as only one carcinoma type, which is considered to arise in the background of a pre-existent benign adenoma. The frequencies of the secondary onset of carcinoma have been recorded to be 6.2% to 8.8% among pleomorphic adenomas, although cellular mechanisms for how carcinoma cells develop in pleomorphic adenomas are poorly understood [1, 2]. In our previous study, we proposed a concept of focal carcinomas in pleomorphic adenoma which is an advanced stage of accumulated atypical cells with P53 over-expressions as an initial stage or a latent form of apparent carcinomas secondarily arising in pleomorphic adenoma . Although pathologists in their daily services of surgical pathology had recognized such singular atypical cells in pleomorphic adenomas, these atypical cells were not always regarded as evidence or the source for malignant transformation [4–6].
Pleomorphic adenomas have been often subjected to cytogenetic and molecular analyses. Among those studies, the PLAG1 (pleomorphic adenoma-related gene), which is located in 8q12, has been investigated most extensively. PLAG1 is consistently rearranged in pleomorphic adenoma by translocations t(3;8)(p21;q12) [7, 8] and t(5;8)(p13;q12) . These translocations have been regarded as one of the major responsible genetic events for the tumorigenesis of pleomorphic adenoma. As another important cancer-related gene, the p53 gene has been most extensively investigated in surgical samples of both benign pleomorphic adenoma, focal carcinoma in pleomorphic adenoma  and carcinoma ex pleomorphic adenoma [10–18], and mutations in the p53 gene have been considered to be responsible for the malignant transformation of pleomorphic adenoma [10–12].
There have been three trials in the literature to establish cell lines/systems from pleomorphic adenomas [19–21] and two from carcinoma ex pleomorphic adenomas [13, 22], in addition to those from mere primary cultures [7–9, 23–27]. Kondo et al.  established an epithelial cell line named Nagoya-78 from a benign pleomorphic adenoma of the lip and showed that the cells contained 62–65 chromosomes with plenty of abnormalities. They also transplanted the cells in hamsters, whose histological phenotypes were malignant myoepitheliomas, to generate tumors within a few weeks. Jaeger et al.  also established a cell line named AP2 from a benign pleomorphic adenoma of the parotid gland, which showed myoepithelial-like characteristics in a three dimensional culture. Another cell line from a palatal pleomorphic adenoma was HPA by Shirasuna et al. . This cell line was revealed ultrastructurally to show a myoepithelial differentiation. These reports described malignant or transformed natures of the cells, while no definite histological characteristics of squamous cell carcinoma were demonstrated. Unfortunately, no further investigations for these cell lines after the initial reports have been conducted, nor has any attention been paid to the gene mutational events in the salivary gland adenoma-carcinoma sequence.
It is thus necessary to analyze the pathogenetic mode of the secondary onset of carcinomas in benign pleomorphic adenomas further in vitro, because most of the previous investigations have been limited to only surgical specimens and primary cultures. In the present study, our aim was to clone cell systems from a pleomorphic adenoma to characterize its transformed cells in various aspects. Since we were successful in establishing five cell systems after a long-period of primary culture from a benign pleomorphic adenoma, we analyzed these cells for cellular differentiation, chromosomal abnormality, p53 gene mutation, and histology of xenografted tumors in nude mice.
A fresh tissue sample was obtained from a parotid gland tumor of a 61-year-old woman. The tumor, measuring 23 × 20 × 15 mm in size, was surgically removed with tumor-free margins. The surgical material was fixed in 10% formalin, cut into about 3–5 mm thick slices using whole-organ sectioning, and embedded in paraffin. Sections 5 μm thick were cut from the cut surfaces of the tumor specimens and stained with hematoxylin and eosin (HE). Macroscopically, the tumor was circumscribed with a fibrous capsule, and was grayish white in color, solid, firm and mucinous in its cut surface. There were no signs of local recurrence or metastasis during her three-year postoperative course. The experimental protocol for isolation and analyses of tumor cells was reviewed and approved by the Niigata University Graduate School of Medical and Dental Sciences Ethical Board. Prior to obtaining the tissue samples, our purpose and plan of the experiment were explained to the patient followed by her consent.
Primary culture and cloning
A tissue slice obtained from the central and maximum cut surface of the surgical material was minced into small pieces. The tissue pieces were treated with 0.1% (v/w) collagenase (F. Hoffmann-La Roche Ltd., Basel, Switzerland) in Dulbecco's minimal essential medium (DMEM, Gibco, Invitrogen. Co., Carlsbad, CA, USA) containing 10% fetal calf serum (Gibco), 50 IU/ml penicillin and 50 μg/ml streptomycin (Gibco) in a 2 ml tube for 8 hrs at 37°C. Pass-through fractions from a nylon mesh filter were washed and plated in 2 ml of DMEM in 35 mm dishes and incubated at 37°C in humidified 5% carbon dioxide/95% air atmosphere. After two weeks, culture media were replaced with fresh ones and thereafter changed every 7 days. After one month, the cells, which had grown to confluence, were split into 25 cm2 flasks. When aggregates of polygonal and bizarre epithelioid cells appeared in the background of spindle-shaped cells in the fourth passage, the cells were split and thereafter passaged every week. After four passages, the cells were served for cloning. The cells prepared as above were plated in 96-well microplates using a conventional method of dilution . Wells with a single cell were observed every 24 hrs by microscope. The culture media were changed every 2 days. After the cells reached subconfluency in the wells, they were transferred into 24 well plates and maintained for up to 1 month until they reached subconfluent conditions, and then the cells were moved to 25 cm2 flasks.
All of the established cell systems were used for immunofluorescence studies. The cells were seeded at a cell concentration of 1.2 × 104 onto each well of chamber slides (Lab-Tek II, 4-well type, Nalge Nunc International, Naperville, IL, USA) and cultivated for 6 days. At day 6 after plating, the chamber slides were fixed and served for immunofluorescence experiments . The primary antibodies consisted of rabbit polyclonal antibodies against human keratin (wide spectrum, Dako, Glostrup, Denmark, diluted at 1:25), and human S-100 protein (Dako, 1:100) and mouse monoclonal antibodies against human cytokeratin (CK) 14 (clone CKB1, IgM, 1: 100, Sigma Chemical Co., St Louis, MO, USA), calpoinin (CALP1, IgG1, 1:50, Dako), and P53 protein (IgG2a, specific to the transcription domain in the NH2-terminal region, clone Bp53-11, Progen Bioteknik GmbH, Heidelberg, Germany). The secondary antibodies were rhodamine-conjugated goat anti-rabbit or mouse IgGs or IgM (ICN Pharmaceuticals, Aurora, OH, USA, 1:50). For control studies, purified non-immune rabbit IgG or mouse IgG2a (Dako) were used instead of the specific primary antibodies. Xenografts of pleomorphic adenoma cell systems in nude mice were also examined immunohistochemically for perlecan, a basement membrane type heparan sulfate proteoglycan, and fibronectin by using rabbit polyclonal antibodies (diluted at 50 μg/ml, respectively)  and the rabbit Envision+/HRP system (Dako). For control studies on the antibodies, the primary antibodies were replaced with preimmune rabbit IgG.
Cellular DNAs were extracted from cells in primary culture and from all of the five established cell systems by using a TRIzol system (Invitrogen). The cells were cultivated for 7 days up to their subconfluency in 25 cm2 flasks, and 1 ml of TRIzol reagent was added to each flask. Total RNAs were then extracted from the cell lysate according to the manufacturer's instructions. After complete removal of the aqueous RNA phase, DNA was isolated from the interphase and phenol-phase. Following precipitation with 0.1 M sodium citrate in 10% ethanol, the precipitants were washed with 70% ethanol, and the pellets were air-dried briefly. The DNA samples dissolved in autoclaved water were stored at -20°C.
Polymerase chain reaction (PCR)
Exons 5-7 of the p53 gene were PCR amplified for sequencing to examine mutational events in cells in primary culture and all of the cloned cell systems. For exon 5, a set of primers (forward, 5'-TTCAA CTCTG TCTCC TTCCT-3'; reverse, 5'-GACCT CTCTG CTGTC CCGAC-3') was used to generate a 323 bp fragment. For exon 6, a set of primers (forward, 5'-GCCTC TGATT CCTCA CTGAT-3'; reverse, 5'-AGAGA CCCTC CTCCC CAATT-3') was used for a 223 bp fragment. For exon 7, a set of primers (forward, 5'-CTTGC CACAG GTCTC CCCAA-3'; reverse, 5'-CGGTG AACGG TGGGA CGTGT-3') was used for a 453 bp fragment. After first denaturation at 94°C for 4 min, the experimental protocol for 35-cycle PCR was performed as follows: denaturation at 94°C for 1 min, annealing at 60°C for 1 min, extension at 72°C for 1 min, and termination with a final extension at 72°C for 7 min. Their sequence primer sets were from the nested primers used in the PCR experiments but with Texas red labeling at their 5'ends.
Direct sequencing of PCR products
All the PCR products for exons 5, 6 and 7 of the p53 gene were subjected to direct sequencing by using Thermo Sequenase Primer Core Cycle Sequencing kits with 7-deaza-dGTP (GE Healthcare Ltd./Amersham, Buckinghamshire, UK). One reaction mixture contained 3 μl of pre-mixes (appropriate nucleotides/reaction buffer/Thermo Sequenase DNA polymerase), 1 μl of the template PCR products purified with GFX PCR DNA and Gel Band Purification kit (Amersham), and 2 μl (2 pM) of Texas red-labeled primers. After denaturation at 95°C for 2 min, the reaction mixture was placed on a thermal cycler for 25 cycles of denaturation at 95°C for 30 sec and annealing/extension at 60°C for 30 sec. The reaction products were dissolved in 3 μl loading buffer and concentrated with a vacuum desiccator. Then, 3 μl of samples for each lane were loaded on a gel [7% Long Ranger (Biowhittaker Molecular Applications, Rockland, ME, USA)/6.1 M urea/1.2 × TBE buffer (0.445 M Tris-HCl, 0.445 M boric acid, 0.01 M EDTA)]. The electrophoresis was performed in a fluorescent DNA sequencer (SQ-5500-S, Hitachi Ltd., Tokyo, Japan) and the sequencing data were analyzed by using the SQ-5500 analysis software ver. 3.03 (Hitachi).
Primary culture cells in the fourth passages and all of the established cell systems in their subconfluent conditions were arrested for 3.5 hrs with 0.06 μg/ml colcemid in DMEM. They were washed two times with PBS and then removed with 0.05% trypsin at 37°C for 5 min. The cells were recovered from culture dishes with DMEM, suspended in 0.075 M KCl at 37°C for 30 min for hypotonic treatment, and then fixed in 1:3 acetic acid/methanol. The cell suspension was dropped onto glass slides to spread chromosomes from cells in the metaphase at room temperature under 50–55% ambient humidity. Slides were stained with 6% Giemsa solution in 0.067 M phosphate buffer (pH 6.8) for visualization of chromosomes. Metaphase spreads from 20 to 50 cells of the primary culture and each cell system were counted for chromosome numbers. Other slides were treated with 0.005% trypsin at 2°C for 8 min. They were washed and then stained with Giemsa solution for visualization of Giemsa (G)-banding. Ten to twenty cells each were analyzed for G-banded karyotypes in all of the cell systems. For control studies, peripheral blood lymphocytes from the patient were cultured in RPMI 1640 (Gibco) containing 10% fetal calf serum (Gibco), 50 IU/ml penicillin and 50 μg/ml streptomycin (Gibco) for 3 days, and then analyzed for chromosome numbers and G-banded karyotypes in the same way as described above.
Fluorescence in-situ hybridization (FISH) analysis of human bacterial artificial chromosome (BAC) clones
BAC correlated with human data in the database and primer sequences for each BAC clone.
Chromosomal location in human
Xenografts in nude mice
To determine in vivo tumorigenicities of the cloned cell systems, SM-AP cells were transplanted in nude mice. Cells in their 9th to 13th in vitro passages at a concentration of 2 × 106 in 0.3 ml culture media were injected into the lateral back wall of female BALB/c (nu/nu) mice at 4 weeks of age (2 mice each per cell system). The animals were housed in clean boxes in a sanitary and ventilated animal room and maintained under constant conditions (at 22°C and in a 12-hr light/dark cycle) with free access to sterilized solid food and autoclaved water. When tumors reached sizes of around 10–15 mm in diameter, they were surgically removed with the animals under ether anesthesia. The excised tumor tissues were fixed in 10% formalin for 24 hrs at 4°C and embedded in paraffin. Serial sections cut at 5 μm from the paraffin blocks were stained with hematoxylin and eosin, Masson's trichrome and immunoperoxidase for perlecan, fibronectin, keratin, S-100 and P53, and then examined histologically. The experimental research by using animals was reviewed and approved by the Niigata University Graduate School of Medical and Dental Sciences Ethical Board.
Tissue sample histology
Establishment of pleomorphic adenoma cell systems
For the first to third cell passages of the primary culture, it took about 2 months for each of the cells to form a confluent monolayer in a 25 cm2 flask ready for splitting. During the period up to the third passage, cells were almost spindle-shaped in isolated colonies but did not show any fascicular modes of packing as seen in fibroblasts (Figure 1C). At the fourth passage, clusters of polygonal cells with ground glass-like cytoplasm started to appear among the spindle-shaped cells (Figure 1D), and the cells reached confluence in 7 days. After four additional passages, during which polygonal cells became enhanced in their atypical features in size and shape of their nuclei and such bizarre cells increased in number in most of the colonies, these cells were served for cloning. From serial dilutions in 96-well microplates, single cells were isolated in individual wells and grew to confluence within one month after plating. They were transferred into 24-well plates and then to a 25 cm2 flask. These cloning procedures were repeated twice, and finally, 5 clones were successfully grown from the primary culture. They were designated as SM-AP1 to SM-AP5. After the cloning procedure, the five cloned cell systems were maintained by passages every 7 days. Their doubling times were approximately 31 hrs irrespective of the five cell systems. They were classified into two groups according to their cell shapes: one was polygonal with squamous epithelial characteristics, which was shared by SM-AP1 (Figure 1E), SM-AP2, and SM-AP3, and the other was short spindle shaped, which was characteristic of SM-AP4 and SM-AP5 (Figure 1F).
Immunofluorescence of clones SM-AP cell systems
Chromosome counts and stemline karyotyps of pleomorphic adenoma cell systems.
Cell numbers counted/karyotyped
Chromosome numbers <ploidy>
XX, -X, -X, add(X)(p11), add(X), add(X)(q11), +1, add(1)(p11)x2, add(1)(q11),
add(1), -2, -2, +3, -3, der(3)add(3)(p11)del(3)(q2?), der(3)add(3)del(3),
der(3)add(3)del(3), -4, add(4)(p11), add(4)(q35), add(4), +5, add(5)(q11), add(5),
-6, -6, add(6)(q11), -8, i(8)(q10), i(8), -9, der(9)t(9;13)(p13;q12)x2, -10,
i(10)(q10), -11, add(11)(p15), +12, add(12)(p11)x2, add(12), -13, -13, -13,
add(13)(p11), add(13), -14, -14, add(14)(q32), add(14), +15, +16, -16,
add(16)(q2?2), add(16), -17, del(17)(p11), -18, add(18)(q11), +19, +19, +20,
+20, +21, add(21)(p11), add(21)(p11), der(21)t(13;21)(q11;p11), -22, -22, -22,
+mar1, +mar2, +mar2, +mar3, +mar5, +04mar.
XX, -X, add(X)(p11), add(X), add(X)(q11), add(X), +1, +1, add(1)(p11)x2,
add(1)(p11), add(1)(q11), add(1), -2, add(2)(p11), idic(2)(q23), -3,
der(3)add(3)(p11)del(3)(q2?), der(3)add(3)del(3), -4, add(4)(q35)x2, +5, add(5)(q11),
add(5), +6, add(6)(q11), del(6)(q25), -8, i(8)(q10)x2, +9, -9,
der(9)t(9;13)(p13;q12), der(9)t(9;13), +10, +10, add(10)(p11), i(10)(q10), i(10),
add(11)(p11), add(11)(p15), +12, add(12)(p11)x2, add(12), -13, -13, -13,
-13, add(13)(p11), add(13), -14, add(14)(q32)x2, +15, -16, add(16)(q2?2), -17,
del(17)(p11), -18, add(18)(q11), add(18)(q21), add(18)(q23), +19, +20, +20, -21,
add(21)(p11), add(21)(p11), add(21)(p11), -22, -22,
+mar1, +mar2, +mar2, +mar3 × 2, +mar4, +07mar.
XXX, -X, add(X)(p11) , add(X)(q11), +1, add(1)(p11)x2, add(1)(q11), add(1),
-2, der(3)add(3)(p11)del(3)(q2?)x2, -4, add(4)(q35)x2, -5, add(5)(q11), add(5),
-6, -6, add(6)(q11), -6, -6, add(6)(q11), -7, -7, der(7;10)(q10;q10), i(7)(q10),
-8, i(8)(q10)x2, -9, der(9)t(9;13)(p13;q12)x2, -10, -10, del(10)(p12), i(10)(q10),
-11, add(11)(p11), -12, add(12)(p11), add(12), -13, -13, -13, -13,
add(13)(p11), -14, -14, add(14)(q32), add(14), +15, -15, -16, -16,
add(16)(q2?2), -17, add(17)(p13), del(17)(p11), -18, -18, add(18)(q11), add(18),
add(18)(q11), add(18)(q21), -19, +20, +20, +20, -21, -21, add(21)(p11),
add(21)(p11), der(21)t(13;21)(q11;p11), -22, -22,
+mar1, +mar2, +mar2, +mar3 , +mar4, +04mar.
XX, -X, add(X)(p11), add(X)(q11), add(X), +1, add(1)(p11), add(1),
add(1)(q11)x2, -2, -3, der(3)add(3)(p11)del(3)(q2?)x2, der(3)add(3)del(3), -4,
add(4)(q35), add(4), +5, -5, add(5)(q11), add(5), -6, add(6)(p11),
add(6)(q11), add(6), +7, add(7)(q11), -8, i(8)(q10), i(8), -9,
der(9)t(9;13)(p13;q12), der(9)t(9;13), -10, i(10)(q10), i(10), -11, add(12)(p11)x2,
-13, -13, -13,-13, add(13)(p11), add(13), add(13)(p11), -14, add(14)(q32),
add(14), der(14)t(1;14)(q11;p11), -16, -16, add(16)(q2?2), add(16), -17, -17, -18,
-18, add(18)(q11), add(18), +19, +20, +20, +20, -21, -21, add(21)(p11),
add(21)(p11), der(21)t(13;21)(q11;p11), -22, -22,
+mar1, +mar2, +mar3, +mar4, +mar5, +03mar.
XX, +add(X)(q11), add(X), add(X)(p11) , add(X), +1, +1, add(1)(p11),
add(1)(p11)x2, add(1)(q11), add(1), i(1)(q10), -2, -2, -3,
der(3)add(3)(p11)del(3)(q2?), der(3)add(3)del(3), der(3)add(3)(p11)del(3)(q2?), -4,
add(4)(q35)x2, +5, add(5)(q11)x2, -6, add(6)(q11), add(6), -8, i(8)(q10)x2,
i(8), +9, add(9)(p11), der(9)t(9;13)(p13;q12), der(9)t(9;13), +10, i(10)(q10)x2,
-11, add(11)(p15)x2, add(11), +12, add(12)(p11)x2, add(12), -13, -13, -13,
add(13)(p11)x2, -14, add(14)(p11), add(14)(p11), add(14)(q32), add(14), +15,
+16, add(16)(q2?2), add(16), -17, -17, del(17)(p11), -18,
-18, add(18)(q11), add(18)(q23), del(18)(q21), +19, +19, +20, +20, +20,
-21, add(21)(p11), add(21)(p11), -22, -22, -22,
+mar1, +mar2, +mar2, +mar3, +mar3, +mar5, +06mar.
XX, -X, -X, -X, add(1)(p11), add(1)(q?12) x2, -2, -3, -3, add(4)(q31.3)x2, +5,
der(5)add(5)(p15.1)add(5)(q22)x2, -6, add(6)(q21)x2, +add(7)(q11.2)x2, i(8)(q10)x2,
-9, add(9)(p11), der(9)t(9;13)(p13;q12)x2, +10, add(10)(p11.1), i(10)(q10)x2, +11,
add(11)(p11.2), add(11)(p15), +12, +12, add(12)(p11.2)x4, -13, -13, -13, -13, -14,
add(14)(q?24)x2, +15, add(16)(q?12.1), -17, ? add(17)(p11.2)x2, -18, -18, +19, +20,
-21, -21, -21, -22, +mar1 × 2, +mar2 × 2, +mar3 × 2, +mar4 × 2, +mar5 × 2 [cp20]
Primary cultured cells shared the same translocations as those of the established SM-AP cell systems, such as der(9)t(9;13)(p13;q12) and add(12)(p11) (Table 2). Peripheral blood lymphocytes from the patient had normal chromosome numbers and karyotype (not shown).
Screening of chromosomal break points for translocation t(9;13)(p13;q12)
P53 gene analysis
Xenografts of SM-AP cells in nude mice
Tumorgenicity of pleomorphic adenoma cell systems.
Number of mice with tumors (n = 2)
Mean time of tumor appearance (weeks)
In the present study, we were successful in establishing the five cell systems, SM-AP1 to SM-AP5, from a benign parotid gland pleomorphic adenoma. We previously suggested a potential of atypical tumor cells scattered in benign pleomorphic adenomas to develop into focal carcinomas and then into tangible forms of carcinoma ex pleomorphic adenoma , although it had been questionable whether the presence of these atypical cells within pleomorphic adenoma could be recognized as sources for the secondary onset of malignancy [4–6].
There have been three trials in the literature to establish cell lines/systems from pleomorphic adenomas in which only their malignant or transformed natures of the cells were reported with no definite histological characterization as squamous cell carcinoma [19–21], and two were from carcinoma ex pleomorphic adenomas [13, 22], in addition to those from mere primary cultures [7–9, 23–27]. In terms of cell shapes in culture, the cell system by Bullerdiek et al. was spindle , and CaPA-4 cells by Fujioka et al.  were squamous epithelial. In our immunohistochemical study, polygonal-shaped SM-AP1 to SM-AP3 were shown to be duct-epithelial, while spindle-shaped SM-AP4 and SM-AP5 were myoepithelial. In addition, their xenografts presented some ductal (SM-AP1-SM-AP3) or myoepithelial (SM-AP1 and SM-AP2 by plasmacytoid appearances) differentiation.
Interestingly, the two cell lines from carcinoma ex pleomorphic adenoma [13, 22] were demonstrated to have characteristics of squamous cell carcinoma when they were transplanted into nude mice, as was also observed in the present study. Although our cell systems lost benign features of pleomorphic and had definite tendencies towards keratinization in xenografts, their histology was not always typical as seen in oral mucosal squamous cell carcinomas ones in terms of their cytoplasm and stroma. SM-AP cells had their characteristic cytoplasm with ground-glass appearances, and their hyaline or myxoid stromata were rich in perlecan and fibronectin and poorly vascularized. These features indicated that they were of pleomorphic adenoma origin. It took longer periods for them to form transplanted tumors, and they had no ulceration or metastasis, indicating that they were not so aggressive.
The five pleomorphic adenoma cell systems cloned in the present study showed aneuploid karyotypes and various kinds of chromosomal abnormalities, of which the translocation, der(9)t(9;13)(p13;q12), was stably shared by all of the clones. As a chromosome 9-related alteration, a reciprocal translocation t(9:12)(p13-21;q13-15) was found in benign pleomorphic adenomas by Mark et al. . In the present study, we were able to restrict the break points of t(9;13)(p13;q12) within 9p13.3 and 13q12.3 in these cell systems. The result indicates that genes located in the distal region of 9p13.3 and the proximal region of 13q12.3 ares missing. The distal region of 9p13.3 is known to contain interferon α cluster (IFNA), a tumor suppressor gene (9p22) , methylthioadenosine phosphorylase (MTAP) (9p21) , and p16 (9p21) , and the break point at 13q12.3 contains IFN-inducible gene, namely the IFI-56K . A role of p16 gene in the secondary onset of malignancy in pleomorphic adenomas has been hypothesized by Suzuki & Fujioka . Since 9p13 rearrangements seem to be generated at the stage of pleomorphic adenoma, pleomorphic adenoma could be regarded as substantially malignant in nature even if it has a benign histological feature. The deletions of 9p22 containing IFNA and 9p21 containing MTAP and p16 genes and 9p allelic losses were also observed in oral squamous cell carcinoma [33, 35–37].
None of the five pleomorphic adenoma cell systems in the present study showed any of these translocations involving 8q12, where PLAG1, one of the most extensively investigated genes in pleomorphic adenomas, is located. Astrom et al.  claimed that the 8q12 abnormalities are not a requirement for the enhanced expression of PLGA1 in pleomorphic adenoma by using primary cultures of both pleomorphic adenoma and carcinoma ex pleomorphic adenoma with or without 8q12 abnormalities. Abnormalities such as t(6,8)(p21-23;q12) , t(9;12)(p13-21;q13-15) , del(5)(q22-23;q32-33), t(10;12)(p15;q14-15) , and t(12;?)(q13-15;?)  found in our cell systems constitute a new finding in pleomorphic adenoma.
Loss of heterozygosity (LOH) has been demonstrated, by using surgical materials, at chromosome arms 8q (52%), 12q (28%), and 17p (14%) in benign pleomorphic adenomas and in adenoma components of carcinoma ex pleomorphic adenoma, whereas the ratios of LOH in 8q, 12q and 17p loci were enhanced up to 69%, 50%, and 69%, respectively, in carcinoma ex pleomorphic adenoma . In our present result, pleomorphic adenoma cell systems tended to decrease numbers of chromosome 17 and abnormalities of add(17)(p11) and add(17)(p13). These chromosomal abnormalities may affect transcription of the p53 gene, which is located in 17p13.
The present result demonstrating that p53 gene products were not detectable immunohistochemically in the five cell systems both in culture and xenografts are consistent with the data from CaPA-4 cells . In the previous reports, immunohistochemical expressions of P53 protein were not always obtained in tumor cells or in the cases examined (3% to 41% for pleomorphic adenoma cases and 41% to 75% for carcinoma ex pleomorphic adenoma cases) [10, 11, 15, 16]. There may be two interpretations for the non-immunopositivity for p53 gene products in our cell systems: one is that the protein expression levels were lower than the sensitivity of the method, and another is that mutated gene products could not be recognized by the antibody, Bp53-11. The latter seems to be more likely in our case because the point mutation in codon #249 in exon 7, which was shared by all of the cell systems, should have generated a nonsense gene product, which could not be recognized by the antibody whose antigenic site is the transcriptional transactivation domain within the NH2-terminal region . Since we confirmed that this point mutation at codon #249 even in cells in the primary culture might have existed before cloning transformed SM-AP cells, this suggests that this mutation plays a role in the tumorigenesis of benign pleomorphic adenoma as well as in its malignant transformation. Interestingly, the G to A transitional point mutation at the next codon #248 found in CaPA-4 cells was also found in the surgical tissue samples from the adenoma portion as well as from the carcinoma portion of their original carcinoma ex pleomorphic adenoma . Thus, the mutations of the p53 gene should be considered to be an early event in the malignant transformation.
The present data suggest that pleomorphic adenoma contains cells with genetic alterations even when its histology is benign and that carcinoma cells may develop from some of the population of benign forms. Whether the atypical cells within benign pleomorphic adenoma  can be the direct source for malignant transformation is hard to say. Since all of the xenografted tumors in nude mice were histologically squamous cell carcinomas, the present establishment of pleomorphic adenoma-derived squamous cell carcinoma cells can be regarded as an in-vitro demonstration of secondary development of malignancy from a benign adenoma. This process may correspond to the clinical form of carcinoma ex pleomorphic adenoma. However, it may be possible at least to speculate that under the circumstances, in which atypical cells are generated, pleomorphic adenoma cells attain some background for the secondary onset of malignancy, which may be generated from the combination of the p53 gene mutation and other chimera genes resulting from the specific translocations involving der(9)t(9; 13)(p13.3; q12.3) and other chromosome abnormalities.
This work was supported in part by Grants-in-Aid for Scientific Research and for Young Scientists from the Japan Society for the Promotion of Science and from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and by a grant for the Promotion of Niigata University Research Projects.
- Gnepp DR, Wening BM: Malignant mixed tumors. Surgical pathology of the Salivary Glands. Edited by: Ellis GL, Auclair PL, Gnepp DR. 1991, Philadelphia: W.B. Saunders, 350-368.Google Scholar
- Ellis GL, Auclair PL: Tumor of the Salivary Glands: Atlas of Tumor Pathology, 3rd Series. 1996, Washington, DC: Armed Forces Institute of Pathology, 228-238.Google Scholar
- Ohtaké S, Cheng J, Ida H, Suzuki M, Ohshiro K, Zhang W, Saku T: Precancerous foci in pleomorphic adenoma of the salivary gland: recognition of focal carcinoma and atypical tumor cells by P53 immunohistochemistry. J Oral Pathol Med. 2002, 31: 590-597. 10.1034/j.1600-0714.2002.00040.x.View ArticlePubMedGoogle Scholar
- Brandwein M, Huvos AG, Dardick I, Thomas MJ, Theise ND: Noninvasive and minimally invasive carcinoma ex mixed tumor: A clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no?) malignant potential. Oral Surg Oral Med Oral Pathol Radiol Endod. 1996, 81: 655-664. 10.1016/S1079-2104(96)80071-0.View ArticleGoogle Scholar
- Auclair PL, Ellis GL: Atypical features in salivary gland mixed tumors: their relationship to malignant transformation. Mod Pathol. 1996, 9: 652-657.PubMedGoogle Scholar
- Takeda Y: An immunohistochemical study of bizarre neoplastic cells in pleomorphic adenoma: its cytological nature and proliferative activity. Pathol Int. 1999, 49: 993-999. 10.1046/j.1440-1827.1999.00968.x.View ArticlePubMedGoogle Scholar
- Kas K, Voz ML, Roijer E, Astrom AK, Meyen E, Stenman G, Ven Van de WJ: Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet. 1997, 15: 170-174. 10.1038/ng0297-170.View ArticlePubMedGoogle Scholar
- Astrom AK, Voz ML, Kas K, Roijer E, Wedell B, Mandahl N, Ven W, Mark J, Stenman G: Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SII as a new fusion partner gene. Cancer Res. 1999, 59: 918-923.PubMedGoogle Scholar
- Voz ML, Astrom AK, Kas K, Mark J, Stenman G, Ven Van de WJ: The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas result in upregulation of PLAG1 gene expression under control of the LIFR promoter. Oncogene. 1998, 16: 1409-1416. 10.1038/sj.onc.1201660.View ArticlePubMedGoogle Scholar
- Deguchi H, Hamano H, Hayashi Y: c-myc, ras p21 and p53 expression in pleomorphic adenoma and its malignant form of the human salivary glands. Acta Pathol Jpn. 1993, 43: 413-422.PubMedGoogle Scholar
- Yamamoto Y, Kishimoto Y, Wistuba II, Virmani AK, Vuitch F, Gazder AF, Albores-Saavedra J: DNA analysis at p53 locus in carcinomas arising from pleomorphic adenomas of salivary glands: comparison of molecular study and p53 immunostaining. Pathol Int. 1998, 48: 265-272. 10.1111/j.1440-1827.1998.tb03904.x.View ArticlePubMedGoogle Scholar
- Righi PD, Li YQ, Deutsch M, Mcdonald JS, Wilson KM, Bejarano P, Stambrook PJ, Osterhage D, Nguyen C, Gluckman JL, Pavelic ZP: The role of the p53 gene in the malignant transformation of pleomorphic adenomas of the parotid gland. Anticancer Res. 1994, 14: 2253-2258.PubMedGoogle Scholar
- Fujioka M, Shimada K, Kitazawa S, Maeda S: Molecular characterization of a novel cancer cell line established from human carcinoma in pleomorphic adenoma (caPA-4). Int J Cancer. 1996, 67: 204-210. 10.1002/(SICI)1097-0215(19960717)67:2<204::AID-IJC10>3.0.CO;2-B.View ArticlePubMedGoogle Scholar
- Weber A, Langhanki L, Schutz A, Gerstner A, Bootz F, Wittekind C, Tannapfel A: Expression profiles of p53, p63, and p73 in benign salivary gland tumors. Virchows Arch. 2002, 441: 428-436. 10.1007/s00428-002-0705-y.View ArticlePubMedGoogle Scholar
- Lewis JE, Olsen KD, Sebo TJ: Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Human Pathol. 2001, 32: 596-604. 10.1053/hupa.2001.25000.View ArticleGoogle Scholar
- Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM: Expression and mutations of p53 in salivary gland tumors. J Oral Pathol Med. 1997, 26: 217-223. 10.1111/j.1600-0714.1997.tb01227.x.View ArticlePubMedGoogle Scholar
- Li X, Tsuji T, Wen S, Mimura Y, Sasaki K, Shinozaki F: Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Cancer. 1997, 79: 2314-2319. 10.1002/(SICI)1097-0142(19970615)79:12<2314::AID-CNCR4>3.0.CO;2-L.View ArticlePubMedGoogle Scholar
- Weber A, Langhanki L, Schutz A, Wittekind C, Bootz F, Tannapfel A: Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland. J Pathol. 2002, 198: 326-334. 10.1002/path.1210.View ArticlePubMedGoogle Scholar
- Kondo T, Muragishi H, Imaizumi M: A cell line from a human salivary gland mixed tumor. Cancer. 1971, 27: 403-410. 10.1002/1097-0142(197102)27:2<403::AID-CNCR2820270225>3.0.CO;2-B.View ArticlePubMedGoogle Scholar
- Jaeger MM, Araujo VC, Kachar B, Jaeger RG: Effect of spatial arrangement of the basement membrane on cultured pleomorphic adenoma cells. Study by immunocytochemistry and electron and conforcal microscopy. Virchows Arch. 1997, 430: 467-477. 10.1007/s004280050057.View ArticlePubMedGoogle Scholar
- Shirasuna K, Sato M, Miyazaki T: A myoepithelial cell line established from a human pleomorphic adenoma arising in minor salivary gland. Cancer. 1980, 45: 297-305. 10.1002/1097-0142(19800115)45:2<297::AID-CNCR2820450217>3.0.CO;2-R.View ArticlePubMedGoogle Scholar
- Bullerdiek J, Hutter KJ, Brandt G, Weinberg M, Belge G, Bartnitzke S: Cytogenetic investigations on a cell line derived from a carcinoma arising in a salivary gland pleomorphic adenoma. Cancer Genet Cytogenet. 1990, 44: 253-262. 10.1016/0165-4608(90)90054-E.View ArticlePubMedGoogle Scholar
- Rohen C, Rogalla P, Meyer-Bolte K, Bartnitzke S, Chila R, Bullerdiek J: Pleomorphic adenomas of the salivary glands: absence of HMGIY rearrangements. Cancer Genet Cytogenet. 1999, 111: 178-181. 10.1016/S0165-4608(98)00241-6.View ArticlePubMedGoogle Scholar
- Mark J, Dahlenfors R, Ekedahl C: Chromosomal Deviations and their specificity in human mixed salivary gland tumors. Anticancer Res. 1981, 1: 49-57.Google Scholar
- Bullerdiek J, Wobst G, Meyer-Bolte K, Chilla R, Haubrich J, Thoode B, Bartnitzke S: Cytogenetic subtyping of 220 salivary gland pleomorphic adenomtas: correlation to occurrence, histological subtype, and in vitro cellular behavior. Cancer Genet Cytogenet. 1993, 65: 27-31. 10.1016/0165-4608(93)90054-P.View ArticlePubMedGoogle Scholar
- Mark J, Dahlenfors R, Wedell B: Impact of the in vitro technique used on the cytogenetic patterns in pleomorphic adenomas. Cancer Genet Cytogenet. 1997, 95: 9-15. 10.1016/S0165-4608(96)00204-X.View ArticlePubMedGoogle Scholar
- Johns MM, Westra WH, Califano JA, Eisele D, Koch WM, Sidransky D: Allelotype of salivary gland tumors. Cancer Res. 1996, 56: 1151-1154.PubMedGoogle Scholar
- MacDougall M, Thiemann F, Ta H, Hsu P, Chen LS, Snead ML: Temperature sensitive simian virus 40 large T antigen immortalization of murine odontoblast cell cultures: establishment of clonal odontoblast cell line. Connect Tissue Res. 1995, 33: 97-103. 10.3109/03008209509016988.View ArticlePubMedGoogle Scholar
- Cheng J, Irié T, Munakata R, Kimura S, Nakamura H, He RG, Liu AR, Saku T: Biosynthesis of basement membrane molecules by salivary adenoid cystic carcinoma cells: an immunofluorescence and confocal microscopic study. Virchows Arch. 1995, 426: 577-586. 10.1007/BF00192112.View ArticlePubMedGoogle Scholar
- Asakawa S, Abe I, Kudoh Y, Kishi N, Wang Y, Kubota R, Kudoh J, Kawasaki K, Minoshima S, Shimizu N: Human BAC library: construction and rapid screening. Gene. 1997, 191: 69-79. 10.1016/S0378-1119(97)00044-9.View ArticlePubMedGoogle Scholar
- Devlin J, Keen AJ, Knowles MA: Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. Oncogene. 1994, 9: 2757-2760.PubMedGoogle Scholar
- Cannon ALA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Patty EM, Bala AE, Olopade OI, Diaz MO, Kwiatkowski DJ, Piepkorn M, Zone JJ, Skolnick MH: Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992, 258: 1148-1152. 10.1126/science.1439824.View ArticleGoogle Scholar
- Suzuki H, Fujioka Y: Deletion of p16 gene and microsatellite instability in carcinoma arising in pleomorphic adenoma of the parotid gland. Diagnostic Mol Pathol. 1998, 7: 224-231. 10.1097/00019606-199808000-00007.View ArticleGoogle Scholar
- Wathelet MG, Szpirer J, Mols CB, Clauss IM, De Wit L, Islam MQ, Levan G, Horisberger MA, Content J, Szpirer C: Cloning and chromosomal location of human genes inducible by type I interferon. Somat Cell Mol Genet. 1988, 14: 415-426. 10.1007/BF01534709.View ArticlePubMedGoogle Scholar
- Nakanishi H, Wang XL, Imai FL, Kato J, Shiiba M, Miya T, Imai Y, Tanzawa H: Localization of a novel tumor supressor gene loci on chromosome 9p21-22 in oral cancer. Anticancer Res. 1999, 19: 29-34.PubMedGoogle Scholar
- van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino k, Koch W, Sidransky D: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res. 1994, 54: 1156-1158.PubMedGoogle Scholar
- Ishwad CS, Ferrell RE, Rossie KN, Appel BN, Johnson JT, Myers EN, Law JC, Srivastava S, Gollin SM: Loss of heterozygosity of the short arm of chromosomes 3 and 9 in oral cancer. Int J Cancer. 1996, 69: 1-4. 10.1002/(SICI)1097-0215(19960220)69:1<1::AID-IJC1>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
- Roijer E, Nordkvist A, Strom AK, Ryd W, Behrendt M, Bullerdiek J, Mark J, Stenman G: Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol. 2002, 160: 433-440.View ArticlePubMedPubMed CentralGoogle Scholar
- El-Naggar AK, Callender D, Coombes MM, Hurr K, Luna MA, Batsakis JG: Molecular genetic alterations in carcinoma ex pleomorphic adenoma: a putative progression model?. Genes Chromosomes Cancer. 2000, 27: 162-168. 10.1002/(SICI)1098-2264(200002)27:2<162::AID-GCC7>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
- Stephen CW, Helmine P, Lane DP: Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol. 1995, 248: 58-78. 10.1006/jmbi.1995.0202.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/247/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.